Aurobindo Pharma subsidiary enters pact with BioFactura for biosimilar ustekinumab
CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma said it has entered into an exclusive license agreement with the US-based BioFactura to commercialize BFI-751, a proposed biosimilar to Stelara (ustekinumab). Ustekinumab is used for treating Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: Arthritis | Biotechnology | Crohn's Disease | Inflammatory Bowel Disease | Pharmaceuticals | Psoriasis | Psoriatic Arthritis | Rheumatology | Stelara | Ulcerative Colitis